{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:11:53Z","timestamp":1768313513411,"version":"3.49.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to characterize the HIV-1 IN gene in a South African context and identify resistance-associated mutations (RAMs) against available first and second generation Integrase strand-transfer inhibitors (InSTIs). We performed genetic analyses on 91 treatment-na\u00efve HIV-1 infected patients, as well as 314 treatment-naive South African HIV-1 IN-sequences, downloaded from Los Alamos HIV Sequence Database. Genotypic analyses revealed the absence of major RAMs in the cohort collected before the broad availability of combination antiretroviral therapy (cART) and INSTI in South Africa, however, occurred at a rate of 2.85% (9\/314) in database derived sequences. RAMs were present at IN-positions 66, 92, 143, 147 and 148, all of which may confer resistance to Raltegravir (RAL) and Elvitegravir (EVG), but are unlikely to affect second-generation Dolutegravir (DTG), except mutations in the Q148 pathway. Furthermore, protein modeling showed, naturally occurring polymorphisms impact the stability of the intasome-complex and therefore may contribute to an overall potency against InSTIs. Our data suggest the prevalence of InSTI RAMs, against InSTIs, is low in South Africa, but natural polymorphisms and subtype-specific differences may influence the effect of individual treatment regimens.<\/jats:p>","DOI":"10.1038\/s41598-018-22914-5","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T15:30:53Z","timestamp":1520868653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa"],"prefix":"10.1038","volume":"8","author":[{"given":"Dominik","family":"Brado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adetayo Emmanuel","family":"Obasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George Mondinde","family":"Ikomey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Cloete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamalendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Engelbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-3338","authenticated-orcid":false,"given":"Ujjwal","family":"Neogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme Brendon","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,16]]},"reference":[{"key":"22914_CR1","doi-asserted-by":"publisher","first-page":"e1001418","DOI":"10.1371\/journal.pmed.1001418","volume":"10","author":"LF Johnson","year":"2013","unstructured":"Johnson, L. F. et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 10, e1001418 (2013).","journal-title":"PLoS Med."},{"key":"22914_CR2","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"A Trickey","year":"2017","unstructured":"Trickey, A. et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 4, e349\u2013e356 (2017).","journal-title":"Lancet HIV"},{"key":"22914_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","volume":"380","author":"RK Gupta","year":"2012","unstructured":"Gupta, R. K. et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet (London, England) 380, 1250\u20138 (2012).","journal-title":"Lancet (London, England)"},{"key":"22914_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/cid\/civ102","volume":"60","author":"R Kantor","year":"2015","unstructured":"Kantor, R. et al. Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. Clin. Infect. Dis. 60, 1541\u20131549 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"22914_CR5","doi-asserted-by":"publisher","first-page":"e0166305","DOI":"10.1371\/journal.pone.0166305","volume":"11","author":"K Steegen","year":"2016","unstructured":"Steegen, K. et al. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One 11, e0166305 (2016).","journal-title":"PLoS One"},{"key":"22914_CR6","unstructured":"Clinton Health Access Initiative, ARV MARKET REPORT Issue 8, 2017. Available at: https:\/\/clintonhealthaccess.org\/content\/uploads\/2017\/09\/2017-ARV-Market-Report_Final-2.pdf (Accessed: 17th January 2018)"},{"key":"22914_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1056\/NEJMoa1311274","volume":"371","author":"NI Paton","year":"2014","unstructured":"Paton, N. I. et al. Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa. N. Engl. J. Med. 371, 234\u2013247 (2014).","journal-title":"N. Engl. J. Med."},{"key":"22914_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1126\/science.287.5453.646","volume":"287","author":"DJ Hazuda","year":"2000","unstructured":"Hazuda, D. J. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646\u201350 (2000).","journal-title":"Science"},{"key":"22914_CR9","doi-asserted-by":"publisher","unstructured":"Rockstroh, J. K. et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J. Acquir. Immune Defic. Syndr. https:\/\/doi.org\/10.1097\/QAI.0b013e31828ace69 (2013).","DOI":"10.1097\/QAI.0b013e31828ace69"},{"key":"22914_CR10","first-page":"339","volume":"8","author":"H Taha","year":"2015","unstructured":"Taha, H., Das, A. & Das, S. Clinical effectiveness of dolutegravir in the treatment of HIV\/AIDS. Infect. Drug Resist. 8, 339\u201352 (2015).","journal-title":"Infect. Drug Resist."},{"key":"22914_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jviromet.2016.10.002","volume":"238","author":"E Heger","year":"2016","unstructured":"Heger, E. et al. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors. J. Virol. Methods 238, 29\u201337 (2016).","journal-title":"J. Virol. Methods"},{"key":"22914_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1128\/AAC.03909-14","volume":"59","author":"T Yoshinaga","year":"2015","unstructured":"Yoshinaga, T. et al. Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection. Antimicrob. Agents Chemother. 59, 397\u2013406 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22914_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/infdis\/jix293","volume":"216","author":"E Ndashimye","year":"2017","unstructured":"Ndashimye, E. High Time to Start Human Immunodeficiency Virus Type 1\u2013Infected Patients on Integrase Inhibitors in Sub-Saharan Africa. J. Infect. Dis. 216, 283\u2013284 (2017).","journal-title":"J. Infect. Dis."},{"key":"22914_CR14","doi-asserted-by":"crossref","unstructured":"Quashie, P. K., Mespl\u00e8de, T. & Wainberg, M. A. Evolution of HIV integrase resistance mutations. Curr. Opin. Infect. Dis. 26, (2013).","DOI":"10.1097\/QCO.0b013e32835ba81c"},{"key":"22914_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.coviro.2014.07.006","volume":"8","author":"JA Grobler","year":"2014","unstructured":"Grobler, J. A. & Hazuda, D. J. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Curr. Opin. Virol. 8, 98\u2013103 (2014).","journal-title":"Curr. Opin. Virol."},{"key":"22914_CR16","unstructured":"US Food&Drug Administration, Approved Drug Products, New Drug Application 204790 Tivicay (Dolutegravir). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204790Orig1s000Approv.pdf. (Accessed: 17th January 2018) (2013)."},{"key":"22914_CR17","unstructured":"Llibre, J. M. et al. Genetic barrier to resistance for dolutegravir. AIDS Reviews 17 (2014)."},{"key":"22914_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi, M. et al. In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55, 813\u201321 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22914_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","volume":"13","author":"F Raffi","year":"2013","unstructured":"Raffi, F. et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect. Dis. 13, 927\u2013935 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"22914_CR20","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley, S. L. et al. Dolutegravir plus Abacavir\u2013Lamivudine for the Treatment of HIV-1 Infection. N. Engl. J. Med. 369, 1807\u20131818 (2013).","journal-title":"N. Engl. J. Med."},{"key":"22914_CR21","unstructured":"World Health Organization (WHO). The use of antiretroviral drugs for treating and preventing hiv infection. 97 Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua\u2009=\u20091. (Accessed: 17th January 2018) (2016)."},{"key":"22914_CR22","unstructured":"UNAIDS. Country Report South Africa. Available at: http:\/\/www.unaids.org\/en\/regionscountries\/countries\/southafrica. (Accessed: 17th January 2018) (2016)."},{"key":"22914_CR23","doi-asserted-by":"crossref","unstructured":"Meintjes, G. et al. Adult antiretroviral therapy guidelines 2017. South. Afr. J. HIV Med. 18, 24 (2017).","DOI":"10.4102\/sajhivmed.v18i1.776"},{"key":"22914_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.virol.2010.03.034","volume":"402","author":"O Goethals","year":"2010","unstructured":"Goethals, O. et al. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 402, 338\u2013346 (2010).","journal-title":"Virology"},{"key":"22914_CR25","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang, M. et al. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob. Agents Chemother. 60, 7086\u20137097 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22914_CR26","doi-asserted-by":"publisher","unstructured":"Van Zyl, G. U. et al. Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First-and Second-Line Antiretroviral Treatment Regimens. https:\/\/doi.org\/10.1371\/journal.pone.0067188 (2013).","DOI":"10.1371\/journal.pone.0067188"},{"key":"22914_CR27","doi-asserted-by":"publisher","first-page":"e90845","DOI":"10.1371\/journal.pone.0090845","volume":"9","author":"GB Jacobs","year":"2014","unstructured":"Jacobs, G. B. et al. HIV-1 Subtypes B and C Unique Recombinant Forms (URFs) and Transmitted Drug Resistance Identified in the Western Cape Province, South Africa. PLoS One 9, e90845 (2014).","journal-title":"PLoS One"},{"key":"22914_CR28","unstructured":"NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES. Annual Overview 2016\/17. 23\u201324 (2017). Available at: http:\/\/www.nicd.ac.za\/wp-content\/uploads\/2017\/03\/NICD_AR_2016_17.pdf (Accessed: 17th January 2018)"},{"key":"22914_CR29","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1128\/AAC.06170-11","volume":"56","author":"C Garrido","year":"2012","unstructured":"Garrido, C. et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob. Agents Chemother. 56, 2873\u20138 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22914_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/TCRM.S2268","volume":"4","author":"Z Temesgen","year":"2008","unstructured":"Temesgen, Z. & Siraj, D. S. Raltegravir: first in class HIV integrase inhibitor. Ther. Clin. Risk Manag. 4, 493\u2013500 (2008).","journal-title":"Ther. Clin. Risk Manag."},{"key":"22914_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-5-74","volume":"5","author":"S-Y Rhee","year":"2008","unstructured":"Rhee, S.-Y. et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 5, 74 (2008).","journal-title":"Retrovirology"},{"key":"22914_CR32","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1128\/AAC.00911-07","volume":"52","author":"A Hombrouck","year":"2008","unstructured":"Hombrouck, A. et al. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob. Agents Chemother. 52, 2069\u201378 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22914_CR33","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.3390\/ijms14035013","volume":"14","author":"PO Bessong","year":"2013","unstructured":"Bessong, P. O. & Nwobegahay, J. Genetic Analysis of HIV-1 Integrase Sequences from Treatment Naive Individuals in Northeastern South Africa. Int. J. Mol. Sci. 14, 5013\u201324 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"22914_CR34","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1089\/aid.2012.0058","volume":"28","author":"MF Oliveira","year":"2012","unstructured":"Oliveira, M. F. et al. Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors. AIDS Res. Hum. Retroviruses 28, 1788\u201392 (2012).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"22914_CR35","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1093\/jac\/dkv202","volume":"70","author":"M Casadell\u00e0","year":"2015","unstructured":"Casadell\u00e0, M. et al. Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1. J. Antimicrob. Chemother. 70, 2885\u20132888 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"22914_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/QAI.0b013e31819df3b3","volume":"51","author":"CB Passaes","year":"2009","unstructured":"Passaes, C. B. et al. Lack of Primary Mutations Associated With Integrase Inhibitors Among HIV-1 Subtypes B, C, and F Circulating in Brazil. JAIDS J. Acquir. Immune Defic. Syndr. 51, 7\u201312 (2009).","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"22914_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0360-7","volume":"14","author":"K Anstett","year":"2017","unstructured":"Anstett, K., Brenner, B., Mesplede, T. & Wainberg, M. A. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 14, 36 (2017).","journal-title":"Retrovirology"},{"key":"22914_CR38","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1128\/AAC.00204-13","volume":"57","author":"W Huang","year":"2013","unstructured":"Huang, W., Frantzell, A., Fransen, S. & Petropoulos, C. J. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob. Agents Chemother. 57, 4105\u201313 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22914_CR39","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1093\/jac\/dkv243","volume":"70","author":"T Doyle","year":"2015","unstructured":"Doyle, T. et al. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J. Antimicrob. Chemother. 70, 3080\u20133086 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"22914_CR40","doi-asserted-by":"crossref","unstructured":"Hardy, I. et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J. Antimicrob. Chemother. 70, (2015).","DOI":"10.1093\/jac\/dku387"},{"key":"22914_CR41","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/JVI.01534-07","volume":"82","author":"K Shimura","year":"2008","unstructured":"Shimura, K. et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137). J. Virol. 82, 764\u201374 (2008).","journal-title":"J. Virol."},{"key":"22914_CR42","doi-asserted-by":"crossref","unstructured":"Abram, M. E. et al. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PLoS One 12, (2017).","DOI":"10.1371\/journal.pone.0172206"},{"key":"22914_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-5-74","volume":"5","author":"S-Y Rhee","year":"2008","unstructured":"Rhee, S.-Y. et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 5, 74 (2008).","journal-title":"Retrovirology"},{"key":"22914_CR44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1128\/AAC.01228-07","volume":"52","author":"I Malet","year":"2008","unstructured":"Malet, I. et al. Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro. Antimicrob. Agents Chemother. 52, 1351\u20131358 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22914_CR45","first-page":"2118","volume":"69","author":"F Danion","year":"2015","unstructured":"Danion, F. et al. Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region. J. Antimicrob. Chemother. 69, 2118\u201322 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"22914_CR46","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/jac\/dkw109","volume":"71","author":"K Anstett","year":"2016","unstructured":"Anstett, K., Cutillas, V., Fusco, R., Mespl\u00e8de, T. & Wainberg, M. A. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. J. Antimicrob. Chemother. 71, 2083\u20132088 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"22914_CR47","doi-asserted-by":"publisher","unstructured":"Neogi, U. et al. Ex vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV-1 non-B subtypes. AIDS 1 https:\/\/doi.org\/10.1097\/QAD.0000000000001726 (2017).","DOI":"10.1097\/QAD.0000000000001726"},{"key":"22914_CR48","doi-asserted-by":"crossref","unstructured":"Rossouw, T. M., Hitchcock, S. & Botes, M. The end of the line? A case of drug resistance to third-line antiretroviral therapy. South. Afr. J. HIV Med. 17, 3 (2016).","DOI":"10.4102\/sajhivmed.v17i1.454"},{"key":"22914_CR49","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/jac\/dku535","volume":"70","author":"S Fourati","year":"2015","unstructured":"Fourati, S. et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J. Antimicrob. Chemother. 70, 1507\u20131512 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"22914_CR50","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn, P. et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382, 700\u2013708 (2013).","journal-title":"Lancet"},{"key":"22914_CR51","doi-asserted-by":"publisher","first-page":"e0128310","DOI":"10.1371\/journal.pone.0128310","volume":"10","author":"PK Quashie","year":"2015","unstructured":"Quashie, P. K., Han, Y.-S., Hassounah, S., Mespl\u00e8de, T. & Wainberg, M. A. Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. PLoS One 10, e0128310 (2015).","journal-title":"PLoS One"},{"key":"22914_CR52","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/jmv.21609","volume":"81","author":"GB Jacobs","year":"2009","unstructured":"Jacobs, G. B. et al. Emergence and diversity of different HIV-1 subtypes in South Africa, 2000\u20132001. J. Med. Virol. 81, 1852\u20131859 (2009).","journal-title":"J. Med. Virol."},{"key":"22914_CR53","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1089\/088922203322231003","volume":"19","author":"P Swanson","year":"2003","unstructured":"Swanson, P., Devare, S. G. & Hackett, J. Molecular Characterization of 39 HIV-1 Isolates Representing Group M (Subtypes A-G) and Group O: Sequence Analysis of gagp24, pol Integrase, and env gp41. AIDS Res. Hum. Retroviruses 19, 625\u2013629 (2003).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"22914_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jviromet.2008.07.008","volume":"153","author":"KV Laethem","year":"2008","unstructured":"Laethem, K. V. et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J. Virol. Methods 153, 176\u2013181 (2008).","journal-title":"J. Virol. Methods"},{"key":"22914_CR55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.meegid.2013.04.032","volume":"19","author":"AC Pineda-Pe\u00f1a","year":"2013","unstructured":"Pineda-Pe\u00f1a, A. C. et al. V. A. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. Infect. Genet. Evol. 19, 337\u2013348 (2013).","journal-title":"Infect. Genet. Evol."},{"key":"22914_CR56","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1093\/nar\/gku739","volume":"42","author":"D Struck","year":"2014","unstructured":"Struck, D., Lawyer, G., Ternes, A.-M., Schmit, J.-C. & Bercoff, D. P. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 42, e144\u2013e144 (2014).","journal-title":"Nucleic Acids Res."},{"key":"22914_CR57","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/bioinformatics\/btu033","volume":"30","author":"A Stamatakis","year":"2014","unstructured":"Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312\u20131313 (2014).","journal-title":"Bioinformatics"},{"key":"22914_CR58","unstructured":"Rhee, S.-Y. et al. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes."},{"key":"22914_CR59","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.aah5163","volume":"355","author":"DO Passos","year":"2017","unstructured":"Passos, D. O. et al. Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome. Science 355, 89\u201392 (2017).","journal-title":"Science"},{"key":"22914_CR60","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/S2352-3018(16)00023-0","volume":"3","author":"A H\u00e4ggblom","year":"2016","unstructured":"H\u00e4ggblom, A., Svedhem, V., Singh, K., S\u00f6nnerborg, A. & Neogi, U. Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden. lancet. HIV 3, e166\u201374 (2016).","journal-title":"lancet. HIV"},{"key":"22914_CR61","doi-asserted-by":"publisher","first-page":"38110","DOI":"10.1074\/jbc.M112.398180","volume":"287","author":"K Singh","year":"2012","unstructured":"Singh, K. et al. Biochemical mechanism of HIV-1 resistance to rilpivirine. J. Biol. Chem. 287, 38110\u201323 (2012).","journal-title":"J. Biol. Chem."}],"updated-by":[{"DOI":"10.1038\/s41598-018-24183-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22914-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22914-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22914-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:32:44Z","timestamp":1671593564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22914-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,16]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["22914"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-22914-5","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-018-24183-8","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,16]]},"assertion":[{"value":"7 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4709"}}